Have an account? Log in.
I don't have an account.
A closer look at VanEck's new TRUF and TRUH ETFs, designed to deliver cleaner healthcare and financials exposure with minimal tracking error.
Major M&A deals this week include: Eli Lilly's $7.8 billion purchase of Centessa Pharmaceuticals; Meanwhile, IO Biotech goes bankrupt.
Ro, the leading direct-to-patient healthcare company, today announced that it is working with Eli Lilly to launch the recently FDA-approved Zepbound® (tirzepatide) KwikPen® nationwide on its platform. The
Eli Lilly & Co shares are down Thursday despite FDA approval of its oral weight-loss drug Foundayo, as geopolitical tensions weigh on markets.
B of A Securities analyst Jason Gerberry maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1293 to $1294.
According to a Bloomberg report, Trump may impose 100% tariffs on drugmakers without pricing deals, as part of a broader push to lower drug costs.
GSAT, XOM, CYCN, LLY, INTC were among the stocks seen trending on Wednesday, April 1, 2026.
Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment, boosting sentiment.
https://www.cnbc.com/2026/04/01/eli-lilly-opposes-trump-mfn-drug-pricing-law-ceo-ricks-says.html
Eli Lilly shares surged after FDA approval of its oral obesity drug Foundayo, boosting growth prospects in the weight-loss market.
Eli Lilly and Company (NYSE:LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used
Centessa Pharma to be acquired by Eli Lilly for $8B. Analyst downgrades rating. Deal includes $6.3B in cash and potential $1.5B in milestones.
Eli Lilly (LLY) shares rallied after finding support at a formed resistance level. They may hit resistance at a former support level.
U.S. stocks bounce sharply on Tuesday as lower Treasury yields and Trump's signals of a potential Iran deal lifted sentiment, with the S&P 500 gaining 1.8% and tech leading.
Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.
Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disordersAcquisition expands Lilly's neuroscience
A senator is selling stocks bought less than a year ago. Here's the list and a look at what he kept instead.
Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:LLY) with a Buy and lowers the price target from $1168 to $1163.
Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA studyLate-breaking results also published in Arthritis
Eli Lilly's deal involves an upfront payment of $115 million to Insilico, with additional payments tied to milestones.
In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years75% of patients achieved a high bar of near-complete skin clearance (EASI-90) and 78%
The Starter plan only unlocks analyses for the 25 stocks tracked over the past month. With the Compact plan, you get access to all stocks from Germany and the USA – with Premium, worldwide access.